

Publications

1. Balazs C, Bokk A, **Molnar I**, Stenszky V, Farid NR: Graves' ophthalmopathy, eye muscle antibodies and HLA antigens. *Expl.Clin. Immunogenet* 1989; 6:190-192.

Impakt faktor: **0.736** (megjelenés éve alapján)

2. **Molnár I**, Balázs C: Effect of lymphokines on bioluminescence activity of polymorphonuclear granulocytes. *Acta Paediatrica Hung* 1988-89; 29/1-2:113-114.

3. **Molnár I**, Németi K, Bokk Á, Stenszky V, Balázs C, Farid NR: Cellular and humoral autoimmune responses against human eye muscle membrane antigen in Graves' disease. *Acta Med Hung* 1990; 47/1-2:43-51.

Impakt faktor: **0.09**

4. **Molnár I**, Balázs C: Comparative study on IgG and IgA antibodies against human thyroid and eye-muscle antigens in Graves' ophthalmopathy. *Acta med Hung* 1991; 48/1-2:13-21.

Impakt faktor: **0.073**

5. **Molnár I**, Balázs C, Szabó E, Czirják L: Evaluation of thyroid function and anti-thyroid autoantibodies in systemic sclerosis. *Acta Dermato-Venereol (Stock)* 1992; 72:112-114.

Impakt faktor: **0.855**

6. **Molnár I**, Balázs C: TSH binding site structures in human eye muscle fractions identified by using covalent-crosslinking. *Biomed Pharmacother* 1992; 46:121-125.

Impakt faktor: **0.453**

7. **Molnár I**, Balázs C, Szabó E, Czirják L: Anti-thyroid antibodies and hypothyroidism in systemic sclerosis. (Letter) *J.Endocrinol Invest* 1992; 15: 311.

Impakt faktor: **0.931**

8. **Molnár I**, Balázs C: The Relationship between anti-human eye muscle antibodies and thyroid function, anti-TSH receptor antibodies and eye symptoms in Graves' ophthalmopathy. *Wien Klin Wochensh* 1992; 104/24:748-752.

Impakt faktor: **0.196**

9. Balázs C, **Molnár I**: In vitro suppression of anti-TSH receptor antibody by autologous anti-idiotypic antibody in patients with Graves' disease. *Acta Microbiol Immunol Hung* 1992; 42(2):163-169.

10. Czirják L, **Molnár I**, Csípő I, Szabolcs M, Mihály A, Szegedi G: Anti-platelet antibodies against

gpIIb/IIIa in systemic sclerosis. *Clin Exp Rheumatology* 1994; 12:527-529.

Impakt faktor: **1.342**

11. **Molnár I**, Balázs C: IgA anti-eye muscle cytosol autoantibodies and the clinical stage in Graves' disease. (Letter) *J Endocrinol Invest* 1994; 17:671.

Impakt faktor: **1.12**

12. Balázs C, **Molnár I**, Bokk Á, Farid NR: Possible role of triiodothyronine in the production of soluble CD4 and CD8 molecules by lymphocytes. In "The Thyroid and Tissue " Eds.: J. Orgiazzi, J. Leclere, U. Hostalek, Schattauer, 1994, p. 219-220.

13. **Molnár I**, Kaczur V, Boros A, Krajczár G, Balázs C: IgA autoantibodies against human eye muscle antigen detected by western blotting and immunohistochemical methods in Graves' disease. *J Endocrinol Invest* 1995; 18:408-414.

Impakt faktor: **1.118**

14. Kaczur V, Vereb Gy, **Molnár I**, Krajczár G, Balázs C: Kinetic characterization of thyroid peroxidase enzyme and its inhibition by autoantibodies. *Acta Microbiol Immunol Hung* 1995; 42(4):345-350.

15. **Molnár I**, Horváth S, Balázs C: Detectable serum IgE levels in Graves' ophthalmopathy. *Eur J Med Res* 1996; 1:543-546.

16. Kaczur V, Vereb Gy, **Molnár I**, Krajczár G, Kiss E, Farid NR, Balázs C: Effect of anti-thyroid peroxidase (TPO) antibodies on thyroid peroxidase activity measured by chemiluminescence technique. *Clin Chemistry* 1997; 43:1392-1396.

Impakt faktor: **3.169**

17. **Molnár I**, Balázs C: High circulating Il-6 in Graves' ophthalmopathy. *Autoimmunity* 1997; 25:91-96.

Impakt faktor: **1.133**

18. Balázs C, Kiss E, Vamos A, **Molnár I**, Farid NR: Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO): a pilot study. *J Clin Endocrinol Metab* 1997; 82:1999-2002.

Impakt faktor: **4.575**

19. **Molnár I**, Balázs C: Effect of radioiodine therapy on the presence of autoantibodies against human thyroid and eye muscle fractions. (Letter) *J Endocrinol Invest* 2000; 23(1):63-64.

Impakt faktor: **0.613**

20. **Molnár I**: Systemic adverse effect of antithyroid drugs.(Letter) *Clin Rheumatol* 2000; 19(1): 78.

Impakt faktor: **0.633**

21. **Molnár I**, Czirják L: Euthyroid sick syndrome and inhibitory effect of sera on the activity of thyroid 5'-deiodinase in systemic sclerosis. *Clin Exp Rheumatol* 2000; 18:719-724.

Impakt faktor: **1.27**

22. Mezosi E, **Molnár I**³, Jakab A⁴, Balogh E¹, Karanyi Z, Pakozdy Z¹, Nagy P¹, Gyory F², Szabo J, Bajnok L, Leovey A, Kakuk G, Nagy EV : CLINICAL STUDY: Prevalence of iodine deficiency and goitre during pregnancy in East Hungary. *Eur J Endocrinol* 2000; 143:479-483.

Impakt faktor: **2.4**

23. **Molnár I**, Balazs C, Szegedi G, Sipka S. : Inhibition of type 2,5'-deiodinase by tumor necrosis factor alpha, interleukin-6 and interferon gamma in human thyroid tissue. *Immunol Lett* 2002; 80(1):3-7.

Impakt faktor: **2.009**

24. **Molnár I**, Bokk Á: Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases. *Cytokine* 2006; 35:109-114.

Impact factor: **2.012**

25. **Molnár I**: The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy *Autoimmunity* 2007; 40(1):31-37.

Impact factor: **1.49**

26. **Molnár I**, Szombathy Z¹, Kovács I¹, Szentmiklósi AJ² : Immunohistochemical studies using immunized guinea pig sera with features of anti-human thyroid, eye and skeletal antibody and Graves'sera. *J Clin Immunol* 2007; 27(2):172-180.

Impact factor: **2.638**

27. Szodoray P, Koczok K, Szanto A, Horvath IF, Nakken B, **Molnár I**, Zehner M : Autoantibodies to novel membrane and cytosolic antigens of the lacrimal gland in primary Sjögren's syndrome. *Clin Rheumatol* 2007; 27(2):195-199.

Impact factor: **1.459**

28. **Molnár I**, Péter F: Autoantibodies against human eye muscle tissue and their clinical relevance in childhood and adulthood Graves' ophthalmopathy. In :Progress in paediatric endocrinology. Ed. Peter F, 2008, pp 81-87.

29. **Molnár I**: Nerve Growth Factor Mediated Effects in the Development of Orbitopathy Associated with Graves' Disease. In: Nerve Growth Factor: New Research, Ed. Guy K. MacIntire, Nova Science Publishers, ISBN: 978-1-60456-992-6, 2008, New York, p 359-375.
30. **Molnár I**: Nervous, immune, endocrine regulatory systems and diseases associated with nerve growth factor co-secretion. In: Volume 1. Horizons in Neuroscience Research, Ed. Costa A. Villalba E, Nova Science Publishers, ISBN:978-1-60692-068-8, 2010, New York, p 1-97.
31. **Molnár I**: Nervous, immune, endocrine regulatory systems and diseases associated with nerve growth factor co-secretion. Nova Science Publishers, ISBN:978-1-60692-068-8, New York, 2010.
32. **Molnár I**, Bohaty I, Somogyiné-Vári É: IL-17A-mediated sRANK ligand elevation involved in postmenopausal osteoporosis. *Osteoporos Int* 2014; 25:783–786.
Impact factor: **4.039**.
33. **Molnár I**, Bohaty I, Somogyiné-Vári É: A high prevalence of increased IL-17A serum levels in postmenopausal estrogen deficiency. *Menopause the Journal of the North American Menopause Society* 2014; 21: 749-752.
Impact factor: **3.163**.
34. **Molnár I**, Kelemen E, Somogyiné-Vári É: The prevalence and characteristics of allergy in autoimmune thyroid diseases. *J Clin Cell Immunol* 2015; 6: 1000306. 6 p.
Impact factor: **2.24**.
35. **Molnár I**, Bohaty I, Somogyiné-Vári É: Serum IL-6, OPG and sRANK ligand levels in premenopausal and postmenopausal women with low estrogen levels. *Cell Immunol Immunother* 2015; 1: excelyticspublishers.com. 5 p.
36. **Molnár I**, Somogyiné-Vári É: Anti-eye muscle IgG and IgM antibodies are associated with eye muscle type 2 deiodinase activities in hyperthyroid Graves' ophthalmopathy. *J Clin Cell Immunol* 2016; 7: 1000460. 5 p.
Impact factor: **2.24**.
37. **Molnár I**: Immune and Metabolic Alterations Associated with Postmenopausal Estrogen Deficiency. *EC Gynaecology RCO* 2017; 01: 01-03.
38. **Molnár I**, Szentmiklósi AJ, Somogyiné-Vári É: Hyperthyroidism in patients with Graves' ophthalmopathy, and thyroidal, skeletal and eye muscle specific type 2 deiodinase enzyme activities. *Exp Clin Endocrinol Diabetes* 2017; 125: 514-521.
Impact factor: **1.685**